Apollo Therapeutics is a collaborative joint venture between three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation) and the technology transfer offices of Imperial College London, University College London and the University of Cambridge.

The £40 million initiative will provide translational funding for biomedical projects developed at these universities. The aim of projects funded by Apollo is to develop promising intellectual property to the point at which it may be licensed out on commercial terms. Projects selected by Apollo will have access to the best industry-standard drug development expertise and development partners. The Apollo partners believe that this will significantly improve the speed and likelihood of university research being translated into novel medicines.

How to apply

Apollo will ultimately operate as an open-funding call, with no deadlines or application windows for researchers. Applications to Apollo from Imperial College London researchers will be managed by the Apollo Imperial Management (AIM) group for which the contacts are set-out below. You may contact any member of this group with a query and they will ensure that you receive a swift response.

It is expected that initial applications will be sourced and screened from the existing “Joint Translational Fund” (Confidence in Concept) portfolio in order to begin operations swiftly. A major internal launch event at Imperial is planned for Q3 2016 when the drug discovery support team will be in place.

In the meantime, if you think you have a project that you would like to be considered for funding from Apollo, please begin by emailing a member of the AIM group with an outline expression of interest. At present, please simply email some basic information on the proposition to enable a discussion and we will get back to you promptly. A more formal ‘EoI’ template form will be put in place in due course.

Who do I contact? - The Apollo-Imperial Management group (AIM) Group

Apollo is a pan-Imperial initiative involving members of the Faculty of Medicine, Faculty of Natural Sciences, Corporate Partnerships and Imperial Innovations. The names and contacts are provided below, feel free to contact any of them with questions or about a potential project proposal you would like to discuss.

Note that the Drug Discovery support team (DDT) for Apollo is in the process of being recruited and their contact details will be added to the above list with time.